AVXL icon

Anavex Life Sciences

11.11 USD
-0.07
0.63%
At close Jul 11, 4:00 PM EDT
After hours
11.00
-0.11
0.99%
1 day
-0.63%
5 days
2.59%
1 month
35.49%
3 months
25.40%
6 months
5.31%
Year to date
-8.56%
1 year
124.90%
5 years
157.18%
10 years
17.57%
 

About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Employees: 2

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

65% more call options, than puts

Call options by funds: $14.7M | Put options by funds: $8.92M

60% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 25

32% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 44

8% more funds holding

Funds holding: 168 [Q4 2024] → 182 (+14) [Q1 2025]

2.1% more ownership

Funds ownership: 34.84% [Q4 2024] → 36.93% (+2.1%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

15% less capital invested

Capital invested by funds: $316M [Q4 2024] → $270M (-$46.6M) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for AVXL.

Financial journalist opinion

Positive
Zacks Investment Research
1 day ago
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice
Neutral
GlobeNewsWire
3 weeks ago
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex”) on behalf of the company's long-term shareholders.
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
Positive
Seeking Alpha
1 month ago
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug may offer years of extra mental lucidity and greater self-sufficiency among Alzheimer's patients. The EU's approval of Blarcamesine could increase Anavex's market value from $800 million to $8 billion.
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
Positive
Seeking Alpha
1 month ago
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early.  These result could lead to European Medicines Agency approval. The benefits of blarcamesine may increase over time due to reduced oxidative stress, though side effects like diziness and confusion may occur. Given the lack of effective Alzheimer's treatments, I cautiously recommend buying Anavex stock based on these promising results.
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Neutral
GlobeNewsWire
1 month ago
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
Neutral
Seeking Alpha
1 month ago
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Neutral
GlobeNewsWire
2 months ago
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Neutral
GlobeNewsWire
2 months ago
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the successful completion of enrollment in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia (ANAVEX3-71-SZ-001, NCT06245213 ). The study has enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B.
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Neutral
GlobeNewsWire
2 months ago
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025.
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
Charts implemented using Lightweight Charts™